Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 4 3Phase 2/3 1Phase 1/2 1

Status

Completed 4Unknown 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 3NET 2Dermatologic 1

Conditions

Neuroendocrine Tumors 2Carcinoma, Merkel Cell 1Carcinoid Tumor 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Completed × lanreotide × Clear all
NCT02795858 2025-02-19

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
43 enrolled 11 charts
Endocrine

Carcinoid Tumor

NCT00326469 2020-11-05

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Ipsen

Phase 2 Completed
30 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02698410 2020-10-01

ATLANT

Ipsen

Phase 2 Completed
40 enrolled 17 charts
EndocrineNET

Neuroendocrine Tumors

NCT02351128 2017-10-18

PHRC-Merkel

University Hospital, Grenoble

Phase 2 Completed
35 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡